127 related articles for article (PubMed ID: 21416695)
1. Liver toxicity of sitaxentan in pulmonary arterial hypertension.
Galiè N; Hoeper MM; Simon J; Gibbs R; Simonneau G;
Eur Heart J; 2011 Feb; 32(4):386-7. PubMed ID: 21416695
[No Abstract] [Full Text] [Related]
2. Liver toxicity of sitaxentan in pulmonary arterial hypertension.
Galiè N; Hoeper MM; Gibbs JS; Simonneau G
Eur Respir J; 2011 Feb; 37(2):475-6. PubMed ID: 21282816
[No Abstract] [Full Text] [Related]
3. Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension.
Lavelle A; Sugrue R; Lawler G; Mulligan N; Kelleher B; Murphy DM; Gaine SP
Eur Respir J; 2009 Sep; 34(3):770-1. PubMed ID: 19720812
[No Abstract] [Full Text] [Related]
4. Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension.
Lee WT; Kirkham N; Johnson MK; Lordan JL; Fisher AJ; Peacock AJ
Eur Respir J; 2011 Feb; 37(2):472-4. PubMed ID: 21282815
[No Abstract] [Full Text] [Related]
5. Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
Don GW; Joseph F; Celermajer DS; Corte TJ
Intern Med J; 2012 Dec; 42(12):1351-4. PubMed ID: 23253000
[TBL] [Abstract][Full Text] [Related]
6. [Hepatotoxicity in patients treated with endothelin receptor antagonists: systematic review and meta-analysis of randomized clinical trials].
Macías Saint-Gerons D; de la Fuente Honrubia C; Montero Corominas D; Catalá-López F
Med Clin (Barc); 2014 Apr; 142(8):333-42. PubMed ID: 23540381
[TBL] [Abstract][Full Text] [Related]
7. An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension.
Owen K; Cross DM; Derzi M; Horsley E; Stavros FL
Regul Toxicol Pharmacol; 2012 Oct; 64(1):95-103. PubMed ID: 22683289
[TBL] [Abstract][Full Text] [Related]
8. Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy.
Hoeper MM; Olsson KM; Schneider A; Golpon H
Eur Respir J; 2009 Jun; 33(6):1518-9. PubMed ID: 19483056
[No Abstract] [Full Text] [Related]
9. The Achilles heel of endothelin receptor therapy for pulmonary arterial hypertension.
Corris PA; Langleben D
Eur Respir J; 2010 Feb; 35(2):460-1; author reply 461. PubMed ID: 20123858
[No Abstract] [Full Text] [Related]
10. Liver toxicity: the Achilles' heel of endothelin receptor antagonist therapy?
Hoeper MM
Eur Respir J; 2009 Sep; 34(3):529-30. PubMed ID: 19720805
[No Abstract] [Full Text] [Related]
11. [Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].
Montani D; Humbert M
Rev Mal Respir; 2010 Feb; 27(2):103-5. PubMed ID: 20206056
[No Abstract] [Full Text] [Related]
12. Drug-related hepatotoxicity.
McIntyre K
N Engl J Med; 2006 May; 354(20):2191-3; author reply 2191-3. PubMed ID: 16710914
[No Abstract] [Full Text] [Related]
13. Sitaxsentan-induced acute severe hepatitis treated with glucocorticoid therapy.
Chin M; Levy RD; Yoshida EM; Byrne MF
Can Respir J; 2012; 19(1):e1-2. PubMed ID: 22332138
[TBL] [Abstract][Full Text] [Related]
14. Exacerbation of AIH in a patient with an AIH/systemic sclerosis overlap syndrome and pulmonary arterial hypertension treated with the endothelin-1 receptor antagonist sitaxentan.
Klein R; Hintz E; Staehler G
BMJ Case Rep; 2012 Jul; 2012():. PubMed ID: 22802555
[TBL] [Abstract][Full Text] [Related]
15. Endothelin receptor antagonists-induced hepatotoxicity.
Macías Saint-Gerons D; de la Fuente Honrubia C; Montero D; Catalá-López F
Intern Med J; 2013 May; 43(5):609-10. PubMed ID: 23668280
[No Abstract] [Full Text] [Related]
16. Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension.
Opitz CF; Ewert R
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():1-9. PubMed ID: 16919004
[TBL] [Abstract][Full Text] [Related]
17. Sitaxsentan sodium for pulmonary hypertension.
MacIntyre IM; Dhaun N; Goddard J; Webb DJ
Drugs Today (Barc); 2008 Aug; 44(8):585-600. PubMed ID: 18846270
[TBL] [Abstract][Full Text] [Related]
18. Sitaxentan: new drug. Pulmonary hypertension: better to continue to use bosentan.
Prescrire Int; 2008 Jun; 17(95):108. PubMed ID: 18630348
[No Abstract] [Full Text] [Related]
19. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
Langleben D
Clin Chest Med; 2007 Mar; 28(1):117-25, viii. PubMed ID: 17338931
[TBL] [Abstract][Full Text] [Related]
20. Selective or nonselective endothelin receptor blockade in pulmonary arterial hypertension.
Wilkins MR
Am J Respir Crit Care Med; 2004 Feb; 169(4):433-4. PubMed ID: 14766656
[No Abstract] [Full Text] [Related]
[Next] [New Search]
